Tiny trial hopes to zap migraines away with implanted nerve device
NCT ID NCT05858801
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a new device called PRIMUS that stimulates nerves in the head and face to treat chronic migraine. Only 7 people with hard-to-treat migraines are taking part. The main goal is to see if the device is safe, not yet if it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRIMUS system (a craniofacial peripheral nerve stimulation device)
What this could lead to
If it works, this could point toward a new drug-free option for people with chronic migraine who haven't found relief from other treatments.
What could go wrong
This is a very early, tiny study (7 people) focused only on safety, not effectiveness. The device may not reduce migraines, and risks like infection or nerve damage are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Delta
Roeselare, Belgium